Infographic: Do Formulary Drug Exclusions Save Money as Promised?

Interclass biologic switching can improve outcomes, but it also increases infection rates.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations.